093sek
-8,8 %
Date:2025-11-24Time:18:00:00Latest report:Q3-2025List:SpotlightTicker:CHOSA
Market Cap:73 msekEnterprise Value:71 msekNet Sales:- msekEarnings:-6,01 msekEmployees:0ISIN:SE0007784319

Ratios

10-year key figure history for CHOSA Oncology turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for CHOSA Oncology with index and moving average MA50 and MA200.

Stockprice:0,93
MA50:1,29
MA200:0,89
Price/MA200:4,7 %
RSI (14):40,0
Price/MA50:-27,7 %

Description

Chosa Oncology is a Danish-Swedish biotechnology company. The company has developed the iCIP platform, which includes a liposomal formulation of cisplatin (LiPlaCis) and the diagnostic tool (DRP) that identifies patients who should benefit most from cisplatin treatment. The achieved clinical phase 2b results mean that the company is ramping up business development to find partners for partnerships or commercial agreements.

Biotechnology